These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 12941579)

  • 1. New and emerging treatment options for multiple sclerosis.
    Polman CH; Uitdehaag BM
    Lancet Neurol; 2003 Sep; 2(9):563-6. PubMed ID: 12941579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies in the treatment of multiple sclerosis.
    Di Pauli F; Berger T; Reindl M
    Curr Med Chem; 2009; 16(36):4858-68. PubMed ID: 19929782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease.
    Fox RJ; Bethoux F; Goldman MD; Cohen JA
    Cleve Clin J Med; 2006 Jan; 73(1):91-102. PubMed ID: 16444920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benign multiple sclerosis: a distinct clinical entity with therapeutic implications.
    Pittock SJ; Rodriguez M
    Curr Top Microbiol Immunol; 2008; 318():1-17. PubMed ID: 18219812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Biological treatment of multiple sclerosis].
    Sørensen PS; Sellebjerg F
    Ugeskr Laeger; 2008 Jun; 170(24):2156-9. PubMed ID: 18565303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach?
    Chofflon M
    BioDrugs; 2005; 19(5):299-308. PubMed ID: 16207071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are statins a treatment option for multiple sclerosis?
    Neuhaus O; Stüve O; Zamvil SS; Hartung HP
    Lancet Neurol; 2004 Jun; 3(6):369-71. PubMed ID: 15157852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current treatment of multiple sclerosis].
    Gout O; Bensa C; Assouad R
    Rev Med Interne; 2010 Aug; 31(8):575-80. PubMed ID: 20579785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Rescue treatments for multiple sclerosis].
    Weinshenker BG
    Rinsho Shinkeigaku; 2009 Nov; 49(11):708-14. PubMed ID: 20030192
    [No Abstract]   [Full Text] [Related]  

  • 15. Dimethyl fumarate for multiple sclerosis.
    Xu Z; Zhang F; Sun F; Gu K; Dong S; He D
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD011076. PubMed ID: 25900414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and future disease-modifying therapies in multiple sclerosis.
    Lim SY; Constantinescu CS
    Int J Clin Pract; 2010 Apr; 64(5):637-50. PubMed ID: 20456216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Monoclonal antibodies for the treatment of multiple sclerosis].
    Sánchez-Seco VG; Casanova Peño I; Arroyo González R
    Med Clin (Barc); 2014 Dec; 143 Suppl 3():30-4. PubMed ID: 25732947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple sclerosis - established and novel therapeutic approaches.
    Ehling R; Berger T; Reindl M
    Cent Nerv Syst Agents Med Chem; 2010 Mar; 10(1):3-15. PubMed ID: 20236038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Possibilities and risks of the monoclonal antibody alemtuzumab as a new treatment option for multiple sclerosis].
    Warnke C; Kieseier BC; Zettl U; Hartung HP
    Nervenarzt; 2009 Apr; 80(4):468-74. PubMed ID: 19296065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on disease-modifying therapies for multiple sclerosis.
    Vargas DL; Tyor WR
    J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.